Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer
Proprietary ROVEr™ platform enables design of next-generation radiopharmaceuticals with tunable pharmacokinetic (PK) properties to maximize therapeutic effect and mitigate systemic toxicities Potential for alpha- or beta-emitting radiopharmaceuticals, for clinically validated and novel cancer targets with a wide range of antigen expression Lead program targeting DLL3 for small cell lung cancer and other solid tumors advancing […]
Abdera skyrockets out of stealth with $142M as radiopharmaceutical ambitions take flight
The nature of Abdera Therapeutics’ platform has elevated expectations that Big Pharma will be queuing up to launch licensing opportunities. Lori Lyons-Williams has always been drawn to working in oncology. For the former Allergan leader and Neumora president, there are few opportunities more impactful than treating cancer—and tough-to-target solid tumors at that. So when given the […]
